聚多巴胺纳米粒子的制备及药物负载研究
Preparation and Drug Loading Study of Polydopamine Nanoparticles
聚多巴胺（Polydopamine, PDA）因良好的生物相容性和光热转换特性，在肿瘤诊疗、靶向给药、生物成像等方向展现出巨大的应用潜力，但是制备条件容易受到多方面因素影响，从而影响到PDA纳米粒子的基本特性。为得到满足体内外应用的纳米粒子基本要求，对反应条件和载药比进行优化，并对其粒径电位、光热效应和载药情况进行表征，以及探究体外光热抗肿瘤活性。结果表明，粒子在pH=9，多巴胺反应浓度为2 mg/mL的时候，即可得到粒径、电位适宜且具有良好光热效应的PDA纳米粒子；PDA与盐酸阿霉素比例为1:6时，可以实现药物的完全包封，此时粒径电位维持在稳定状态；上述结果表明，优化制备条件后得到的PDA纳米粒子确保在粒径、电位适宜的基础上，具有良好光热特性和高效载药能力，为后续在纳米制剂方面的应用提供参考价值。
医药卫生理论肿瘤学药学生物化学生物物理学
聚多巴胺光热效应：药物负载
邰丽娟,李亚超.聚多巴胺纳米粒子的制备及药物负载研究[EB/OL].(2025-09-19)[2025-09-28].http://www.paper.edu.cn/releasepaper/content/202509-20.点此复制
Polydopamine (PDA) has shown great application potential in fields such as tumor diagnosis and treatment, targeted drug delivery, and biological imaging owing to its excellent biocompatibility and photothermal conversion properties. However, its preparation conditions are susceptible to various factors, which in turn affect the basic properties of polydopamine nanoparticles (PDA NPs). To obtain PDA NPs that meet the basic requirements for in vitro and in vivo applications, the reaction conditions and drug-loading ratio were optimized and characterized. The results showed that when the reaction was conducted at pH 9 with a dopamine concentration of 2 mg/mL, PDA NPs with appropriate particle size, suitable zeta potential, and excellent photothermal effect could be obtained. When the mass ratio of polydopamine to doxorubicin hydrochloride (DOX HCl) was 1:6, complete encapsulation of the drug was achieved, and the particle size and zeta potential of the NPs remained stable at this ratio.These results indicate that the PDA NPs prepared under the optimized conditions not only have appropriate particle size and zeta potential but also exhibit excellent photothermal properties and high-efficiency drug-loading capacity. This study provides a reference for the subsequent application of PDA NPs in the field of nanoformulations.
PolydopaminePhotothermal effectDrug loading
展开英文信息
评论